Safety and Efficacy of Statins in Asians

American Journal of Cardiology

Volumn 99, Issue 3, 2007, Pages 410-414

  Liao, James K ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ASIAN; CHINESE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DYSLIPIDEMIA; EUROPEAN AMERICAN; GENETIC VARIABILITY; HUMAN; ISCHEMIC HEART DISEASE; JAPANESE; KOREAN; LIVER DISEASE; LOW DRUG DOSE; MUSCLE DISEASE; MYOPATHY; PRIORITY JOURNAL; RACE DIFFERENCE; RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT;

ASIAN CONTINENTAL ANCESTRY GROUP; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; TREATMENT OUTCOME; WORLD HEALTH;

EID: 33846464226     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.08.051     Document Type: Review

References (53)

1. Kita T. Coronary heart disease risk in Japan: an east/west divide?. Eur Heart J 6 suppl (2004) A8-A11
2. Hata Y., Mabuchi H., Saito Y., Itakura H., Egusa G., Ito H., Teramoto T., Tsushima M., Tada N., Oikawa S., et al. Report of the Japan Atherosclerosis Society (JAS) guideline for diagnosis and treatment of hyperlipidemia in Japanese adults. J Atheroscler Thromb 9 (2002) 1-27
3. Tan C.-E., Ma S., Wai D., Chew S.-K., and Tai E.-S. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?. Diabetes Care 27 (2004) 1182-1186
4. Thomas G.N., Ho S.Y., Janus E.D., Lam K.S., Hedley A.J., and Lam T.H. for the Hong Kong Cardiovascular Risk Factor Prevalence Study Steering Committee. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population. Diabetes Res Clin Pract 67 (2005) 251-257
5. Choi S.H., Ahn C.W., Cha B.S., Chung Y.-S., Lee K.W., Lee H.C., Huh K.B., and Kim D.J. The prevalence of the metabolic syndrome in Korean adults: comparison of WHO and NCEP criteria. Yonsei Med J 46 (2005) 198-205
6. Wu C.-C., Sy R., Tanphaichitr V., Hin A.T.T., Suyono S., and Lee Y.-T. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol: a multinational, multicenter, double-blind study. J Formos Med Assoc 101 (2002) 478-487
7. Tan C.E., Loh L.M., and Tai E.S. Do Singapore patients require lower doses of statins?. The SGH Lipid Clinic experience. Singapore Med J 44 (2003) 635-638
8. Matsuzawa Y., Kita T., Mabuchi H., Matsuzaki M., Nakaya N., Oikawa S., Saito Y., Sasaki J., Shimamoto K., Itakura H., and J-LIT Study Group. Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients: implication of the J-LIT study, a large scale nationwide cohort study. Circ J 67 (2003) 287-294
9. Morales D., Chung N., Zhu J.-R., Sangwatanaroj S., Yin W.-H., Lee K., Davies M.J., Shah A., Loeys T., and Bilheimer D. Efficacy and safety of simvastatin in Asian and non-Asian coronary heart disease patients: a comparison of the GOALLS and STATT studies. Curr Med Res Opin 20 (2004) 1235-1243
10. Lee E., Ryan S., Birmingham B., Zalikowski J., March R., Ambrose H., Moore R., Lee C., Chen Y., and Schneck D. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78 (2005) 330-341
11. Kim K., Johnson J.A., and Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 44 (2004) 1083-1105
12. Poolsup N., Li Wan Po A., and Knight T.L. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther 25 (2000) 197-220
13. Guengerich F.P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39 (1999) 1-17
14. Lamba J.K., Lin Y.S., Schuetz E.G., and Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54 (2002) 1271-1294
15. Wang A., Yu B.N., Luo C.H., Tan Z.R., Zhou G., Wang L.S., Zhang W., Li Z., Liu J., and Zhou H.H. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur J Clin Pharmacol 60 (2005) 843-848
16. Rodriguez I., Abernethy D.R., and Woosley R.L. P-glycoprotein in clinical cardiology. Circulation 99 (1999) 472-474
17. Yu D.K. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 39 (1999) 1203-1211
18. Kim R.B. Transporters and xenobiotic disposition. Toxicology 181-182 (2002) 291-297
19. Kim R.B., Wandel C., Leake B., Cvetkovic M., Fromm M.F., Dempsey P.J., Roden M.M., Belas F., Chaudhary A.K., Roden D.M., et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 16 (1999) 408-414
20. Xie H.-G., Kim R.B., Wood A.J.J., and Stein C.M. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 41 (2001) 815-850
21. Johnson J.A. Influence of race or ethnicity on pharmacokinetics of drugs. J Pharm Sci 86 (1997) 1328-1333
22. Bogman K., Peyer A.K., Torok M., Kusters E., and Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 132 (2001) 1183-1192
23. Martin P.D., Dane A.L., Nwose O.M., Schneck D.W., and Warwick M.J. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol 42 (2002) 1116-1121
24. Nishizato Y., Ieiri I., Suzuki H., Kimura M., Kawabata K., Hirota T., Takane H., Irie S., Kusuhara H., Urasaki Y., et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73 (2003) 554-565
25. Hsiang B., Zhu Y., Wang Z., Wu Y., Sasseville V., Yang W.-P., and Kirchgessner T.G. A novel human hepatic organic anion transporting polypeptide (OATP2). J Biol Chem 274 (1999) 37161-37168
26. Mwinyi J., Johne A., Bauer S., Roots I., and Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 75 (2004) 415-421
27. Takeda M., Noshiro R., Onozato M.L., Tojo A., Hasannejad H., Huang X.L., Narikawa S., and Endou H. Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. Eur J Pharmacol 483 (2004) 133-138
28. Chan P., Huang T.Y., Tomlinson B., Lee C., and Lee Y.S. Short-term safety and efficacy of low-dose simvastatin in elderly patients with hypertensive hypercholesterolemia and fasting hyperinsulinemia. J Clin Pharmacol 37 (1997) 496-501
29. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group. Efficacy of atorvastatin in primary hypercholesterolemia. Am J Cardiol 79 (1997) 1248-1252
30. Saito Y., Goto Y., Dane A., Strutt K., Raza A., and Japan Rosuvastatin Study Group. Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia. J Atheroscler Thromb 10 (2003) 329-336
31. Wang K.-Y., and Ting C.-T. A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol. Jpn Heart J 42 (2001) 725-738
32. Yamamoto A., Arakawa K., Sasaki J., Matsuzawa Y., Takemura K., Tsushima M., Fujinami T., Mabuchi H., Itakura H., Yamada N., et al., Rosuvastatin Dose-Ranging Trialist Group. Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study. J Atheroscler Thromb 9 (2002) 48-56
33. Garmendia F., Brown A.S., Reiber I., and Adams P.C. Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study). Curr Med Res Opin 16 (2000) 208-219
34. Itoh T., Matsumoto M., Hougaku H., Handa N., Tsubakihara Y., Yamada Y., Imaizumi M., Hoshi M., Shimazu Y., Hori M., et al., Simvastatin Study Group. Effects of low-dose simvastatin therapy on serum lipid levels in patients with moderate hypercholesterolemia: a 12-month study. Clin Ther 19 (1997) 487-497
35. Mabuchi H., Nohara A., Higashikata T., Ueda K., Bujo H., Matsushima T., Ikeda Y., and Nii M. Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia. J Atheroscler Thromb 11 (2004) 152-158
36. Chung N., Cho S.-Y., Choi D.-H., Zhu J.-R., Lee K., Lee P.-Y., Lee S.-H., Lee S., Wang J.-J., Yin W.-H., et al. STATT: a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease. Clin Ther 23 (2001) 858-870
37. Teramoto T., Goto Y., Kurokawa K., Nakamura H., Yoshida S., Saito Y., Nakaya N., Itakura H., Takaku F., Yamada N., et al. Clinical efficacy of fluvastatin for hyperlipidemia in Japanese patients. Am J Cardiol 76 suppl (1995) 33A-36A
38. Tomlinson B., Mak T.W.L., Tsui J.Y.Y., Woo J., Shek C.C., Critchley J.A.J.H., and Masarei J.R.L. Effects of fluvastatin on lipid profile and apolipoproteins in Chinese patients with hypercholesterolemia. Am J Cardiol 76 suppl (1995) 136A-139A
39. Yoshida H., Yanai H., Shoda T., Furutani N., Sato N., and Tada N. Effects of simvastatin 20 mg/d on serum lipid profiles in Japanese hyperlipidemic patients: a prospective, open-label pilot study. Curr Ther Res 66 (2005) 613-629
40. Kyushu Lipid Intervention Study Group. Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study. J Atheroscler Thromb 7 (2000) 110-121
41. Sasaki J., Arakawa K., Iwashita M., Matsushita Y., Kono S., and Kyushu Lipid Intervention Study (KLIS) Group. Reduction in serum total cholesterol and risks of coronary events and cerebral infarction in Japanese men: the Kyushu Lipid Intervention Study. Circ J 67 (2003) 473-478
42. Nakamura H. Management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study). Circulation 112 (2005) 3364
43. Ito H., Ouchi Y., Ohashi Y., Saito Y., Ishikawa T., Nakamura H., and Orimo H. A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the Pravastatin Anti-Atherosclerosis Trial in the Elderly (PATE). J Atheroscler Thromb 8 (2001) 33-44
44. Ishikawa T., Ito H., Ouchi Y., Ohashi Y., Saito Y., Nakamura H., Orimo H., and PATE Investigators. Increased risk for cardiovascular outcomes and effect of cholesterol-lowering pravastatin therapy in patients with diabetes mellitus in the Pravastatin Anti-Atherosclerosis Trial in the Elderly (PATE). Curr Ther Res 66 (2005) 48-65
45. Saito Y., Shirai K., Sasaki N., Shinomiya M., Yoshida S., and Committee of the Chiba Lipid Intervention Program Study. Prognosis of hypercholesterolemic patients taking pravastatin for five years: the Chiba Lipid Intervention Program (CLIP) Study. J Atheroscler Thromb 9 (2002) 99-108
46. Koizumi J., Shimizu M., Miyamoto S., Origasa H., Mabuchi H., and Hokuriku Lipid CHD Study Group. Effect of pravastatin-induced LDL-cholesterol reduction on coronary heart disease and cerebrovascular disease in Japanese: Hokuriku Lipid Coronary Heart Disease Study-Pravastatin Atherosclerosis Trial (Holicos-PAT). J Atheroscler Thromb 9 (2002) 251-259
47. Matsuzaki M., Kita T., Mabuchi H., Matsuzawa Y., Nakaya N., Oikawa S., Saito Y., Sasaki J., Shimamoto K., Itakura H., and J-LIT Study Group. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia: primary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J 66 (2002) 1087-1095
48. Mabuchi H., Kita T., Matsuzaki M., Matsuzawa Y., Nakaya N., Oikawa S., Saito Y., Sasaki J., Shimamoto K., Itakura H., and J-LIT Study Group. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J 66 (2002) 1096-1100
49. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., and Gotto Jr. A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 279 (1998) 1615-1622
50. Sever P.S., Dahlöf B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., et al., ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
51. Horiuchi H., Kita T., Mabuchi H., Matsuzaki M., Matsuzawa Y., Nakaya N., Oikawa S., Saito Y., Sasaki J., Shimamoto K., et al. Primary cardiovascular events and serum lipid levels in elderly Japanese with hypercholesterolemia undergoing 6-year simvastatin treatment: a subanalysis of the Japan Lipid Intervention Trial. J Am Geriatr Soc 52 (2004) 1981-1987
52. Crestor (rosuvastatin calcium) Prescribing Information. Available at: http://www.astrazeneca-us.com/pi/crestor.pdf. Accessed on December 13, 2006..
53. Saito M., Hirata-Koizumi M., Urano T., Miyake S., and Hasegawa R. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. J Clin Pharm Ther 30 (2005) 21-37